M.A. Med Alliance SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
M.A. Med Alliance SA - overview
Established
2008
Location
Nyon, -, Switzerland
Primary Industry
Medical Devices & Equipment
About
Based in Switzerland, M. A. MedAlliance SA develops innovative solutions in cardiovascular health, focusing on enhancing patient outcomes through advanced medical devices and technologies. M.
A. MedAlliance SA is a company specialized in interventional cardiovascular products. Established in 2008, it is headquartered in Nyon, Switzerland. The company has undergone significant changes, highlighted by its acquisition by Cordis Corporation in a deal valued at up to USD 1.
135 billion, finalized in October 2022. The deal involved an upfront payment of USD 235 mn, with additional milestones based on regulatory and commercial achievements extending through 2029. Jeffrey Jump and Susanne Meis currently serve as the company's CEOs. Prior to this acquisition, M.
A. MedAlliance was backed by Trustar Capital and has been involved in 2 deals to date. M. A.
MedAlliance SA focuses on the development and manufacturing of interventional cardiovascular products aimed at improving patient care. Their offerings include advanced drug-eluting balloons, vascular closure devices, guidewires, and diagnostic catheters, utilized in various cardiac and peripheral interventions. The SELUTION SLR™ Drug-Eluting Balloon, featuring proprietary technology for controlled sirolimus release, is among their key products. M.
A. MedAlliance primarily caters to healthcare professionals, hospitals, and medical institutions across over 60 countries, including important markets in Europe, North America, and Asia. M. A.
MedAlliance generates revenue through direct sales to healthcare providers and institutions, leveraging a B2B transaction model. Their revenue streams are driven by partnerships with hospitals and clinics, often involving bulk purchasing agreements. Specific products like the MYNX CONTROL™ Vascular Closure Device and RAIN Sheath™ Transradial Introducer contribute significantly to their sales, reflecting the advanced nature of their medical devices and the critical applications they serve in healthcare. Looking ahead, M.
A. MedAlliance aims to expand its product portfolio with new offerings designed to enhance cardiovascular care. The recent acquisition by Cordis Corporation will facilitate the launch of clinical study programs and publication plans to better serve their clients. Additionally, the company plans to target new geographic regions for market expansion, leveraging its innovative technologies to address the needs of healthcare providers globally.
The acquisition's rationale centers on accelerating patient impact and facilitating growth initiatives that will support these strategic plans.
Current Investors
Trustar Capital
Primary Industry
Medical Devices & Equipment
Sub Industries
Healthcare IT, Cardiology, Therapeutic Devices, Specialty Pharmaceuticals
Website
www.medalliance.com
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
M.A. Med Alliance SA - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | M.A. Med Alliance SA | - | ||||||||
| Trade Sale | Completed | M.A. Med Alliance SA | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.